Voyager Therapeutics, Inc.

– IND filing expected in mid-2025 – LEXINGTON, Mass. , Dec. 06, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead development candidate for its The post Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program first appeared on Voyager Therapeutics.

– GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing – – SOD1 ALS gene therapy program on track for development candidate selection by end of year – – Conference call at 4:30 p.m. ET today – LEXINGTON, Mass. , Nov. The post Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results first appeared on Voyager Therapeutics.

CAMBRIDGE, Mass. , Oct. 30, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report third quarter 2023 financial and operating results after market close on The post Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast first appeared on Voyager Therapeutics.

CAMBRIDGE, Mass. , Sept. 25, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Executive Officer Alfred W. Sandrock , Jr., M.D., Ph.D., will present at the The post Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference first appeared on Voyager Therapeutics.

CAMBRIDGE, Mass. , Sept. 07, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with three newly-hired employees that, among other things, provide The post Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) first appeared on Voyager Therapeutics.

CAMBRIDGE, Mass. , Aug. 30, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that management will participate in the following investor conferences: Wells Fargo Health The post Voyager Therapeutics to Participate in Upcoming Investor Conferences first appeared on Voyager Therapeutics.

CAMBRIDGE, Mass. , Aug. 08, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into an employment agreement with Beth Shafer , Ph.D., M.A., M.Phil . The post Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) first appeared on Voyager Therapeutics.

CAMBRIDGE, Mass. , Aug. 07, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics , Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Beth Shafer , Ph.D., M.A., M.Phil ., as Chief Business Officer (CBO). The post Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer first appeared on Voyager Therapeutics.

– Introduced new vectorized anti-Aβ antibody gene therapy research initiative, expanding Alzheimer’s disease portfolio – – Executed license agreement with Sangamo for prion disease treatment – – Presented validating preclinical results including increased brain transduction of IV-administered The post Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results first appeared on Voyager Therapeutics.